Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.2495 EUR 2.25%
Market Cap: 31.1m EUR
SIGHT
/
Balance Sheet
/
Cash & Cash Equivalents

Gensight Biologics SA
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Gensight Biologics SA
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Gensight Biologics SA
PAR:SIGHT
Cash & Cash Equivalents
€6.9m
CAGR 3-Years
-50%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Cash & Cash Equivalents
€156.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innate Pharma SA
PAR:IPH
Cash & Cash Equivalents
€70m
CAGR 3-Years
-12%
CAGR 5-Years
-14%
CAGR 10-Years
-1%
G
Genfit SA
PAR:GNFT
Cash & Cash Equivalents
€61.6m
CAGR 3-Years
-16%
CAGR 5-Years
-26%
CAGR 10-Years
-1%
Inventiva SA
PAR:IVA
Cash & Cash Equivalents
€10.1m
CAGR 3-Years
-52%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Cash & Cash Equivalents
€86.6m
CAGR 3-Years
6%
CAGR 5-Years
61%
CAGR 10-Years
19%

Gensight Biologics SA
Glance View

Market Cap
31.1m EUR
Industry
Biotechnology

GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).

SIGHT Intrinsic Value
0.2383 EUR
Overvaluation 4%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Gensight Biologics SA's Cash & Cash Equivalents?
Cash & Cash Equivalents
6.9m EUR

Based on the financial report for Jun 30, 2024, Gensight Biologics SA's Cash & Cash Equivalents amounts to 6.9m EUR.

What is Gensight Biologics SA's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-13%

Over the last year, the Cash & Cash Equivalents growth was 580%. The average annual Cash & Cash Equivalents growth rates for Gensight Biologics SA have been -50% over the past three years , -13% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 238,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.